OEL Fastrac Catalog

Please note, this OEL/ADE monograph also applies to hydroxychloroquine sulfate (CAS RN 747-36-4) and hydroxychloroquine diphosphate (CAS RN 6168-85-0). Hydroxychloroquine is an aminoquinoline, similar to chloroquine, and exists as a racemic mixture of the R-enantiomer and S-enantiomer. Hydroxychloroquine is a chemotherapeutic agent indicated for the prophylaxis of malaria where chloroquine resistance is not reported, for the treatment of uncomplicated malaria (caused by Plasmodium falciparum, Plasmodium malariae, Plasmodium ovale, or Plasmodium vivax), for chronic discoid lupus erythematosus, systemic lupus erythematosus (SLE), acute rheumatoid arthritis (RA), and chronic RA. Hydroxychloroquine was investigated in adults hospitalized with respiratory symptoms from severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2). Hydroxychloroquine sulfate is also used in similar doses for the treatment of lightsensitive skin eruptions, but treatment should only be given during periods of maximum exposure to light.

Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.

Why do you need this OEL Fastrac monograph?

OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:

• The numerical OEL and control band assignment needed to determine the level of required engineering controls and personal protective equipment
• A listing of all cited references utilized in the derivation of the OEL and ADE
• An expert review and discussion with respect to the critical endpoints of concern, the rationale for the choice of endpoints, and dose that is to be used in the derivation of the ADE (PDE), as required by the EMA's Guideline on setting health-based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities

Benefits of OEL Fastrac monographs

• Fully documented. Over 20 pages in length, with calculations and cited references.
• Save time! Unsurpassed delivery with instant download.
• Save money. Similar documents cost 5-12 times as much.
• Stay current. Automatic notification of revisions.

How to order

To order an OEL/ADE monograph for Hydroxychloroquine, just click the ADD TO CART button.

HBEL

If you're wondering about HBEL, we have something for you.